Focused On-demand Library for Glutamate receptor 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P48058

UPID:

GRIA4_HUMAN

Alternative names:

AMPA-selective glutamate receptor 4; GluR-D; Glutamate receptor ionotropic, AMPA 4

Alternative UPACC:

P48058; Q86XE8

Background:

Glutamate receptor 4, also known as AMPA-selective glutamate receptor 4, GluR-D, and Glutamate receptor ionotropic, AMPA 4, plays a pivotal role in the central nervous system. It acts as a ligand-gated ion channel, essential for excitatory synaptic transmission. The binding of L-glutamate to this receptor induces a conformational change, leading to the opening of the cation channel and conversion of the chemical signal to an electrical impulse.

Therapeutic significance:

The protein is linked to a neurodevelopmental disorder with or without seizures and gait abnormalities, highlighting its critical role in neurological health. Understanding the role of Glutamate receptor 4 could open doors to potential therapeutic strategies for treating such disorders.